Annexon Biosciences Stock

annexonbio.comHealthcare / BioTech & PharmaFounded: 2011Funding to Date: $154MM

Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain.

Register To Buy and Sell Shares

For more details on financing and valuation for Annexon Biosciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Annexon Biosciences’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Annexon Biosciences.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Jennifer Lew
Chief Financial Officer
Ted Yednock Ph.D
Chief Scientific Officer & Executive Vice President
Sanjay Keswani
Chief Medical Officer
Douglas Love JD
Chief Executive Officer, President & Board Member
Lesley Stolz Ph.D
Chief Business Officer

Board Members

Carol Gallagher
New Enterprise Associates
Giovanni Ferrara
Novartis Venture Fund
Stacie Weninger Ph.D
Emmett Cunningham Ph.D
Blackstone Life Sciences
Douglas Love JD
Frank Torti MD
New Enterprise Associates
Ricky Sun Ph.D
Bain Capital
William Young
Blackstone Life Sciences
Campbell Murray MD
Novartis Venture Fund
Muneer Satter JD
Satter Foundation
Thomas Wiggans

Frequently Asked Questions About Annexon Biosciences’ Stock

plusminus
Can you buy Annexon Biosciences’ stock?
Annexon Biosciences is not publicly traded on NYSE or NASDAQ in the U.S. To buy Annexon Biosciences’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Annexon Biosciences’ stock?
Yes, you can sell stock of a private company like Annexon Biosciences. Forge can help you sell your Annexon Biosciences stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Annexon Biosciences’ stock price?
Annexon Biosciences is a privately held company and therefore does not have a public stock price. However, you may access Annexon Biosciences’ private market stock price with Forge Data.
plusminus
What is Annexon Biosciences’ stock ticker symbol?
Annexon Biosciences does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Biopharmaceutical Company Annexon Biosciences Closes $44M Series B Funding |FinSMEs
Annexon Biosciences, a South San Francisco, CA-based biopharmaceutical company developing classical complement pathway inhibitors to treat neurodegenerative disorders, closed $44m Series B financing round. The round was led by new investor New Enterprise Associates (NEA), with participation from Correlation Ventures and existing investors Novartis Venture Fund, Clarus, and Satter Investment Management, LLC. In conjunction with …
Updated on: May 17, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.